1. Home
  2. NAAS vs NEUP Comparison

NAAS vs NEUP Comparison

Compare NAAS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NaaS Technology Inc.

NAAS

NaaS Technology Inc.

HOLD

Current Price

$3.50

Market Cap

9.0M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.30

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAAS
NEUP
Founded
2019
1996
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
10.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
NAAS
NEUP
Price
$3.50
$4.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
32.6K
89.2K
Earning Date
03-31-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$21,817,052.00
$15,649,448.00
Revenue This Year
$378.49
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.96
$2.90
52 Week High
$40.32
$21.40

Technical Indicators

Market Signals
Indicator
NAAS
NEUP
Relative Strength Index (RSI) 49.26 37.82
Support Level $3.31 $4.10
Resistance Level $3.89 $4.65
Average True Range (ATR) 0.26 0.27
MACD -0.01 0.23
Stochastic Oscillator 49.82 21.82

Price Performance

Historical Comparison
NAAS
NEUP

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: